Satisfaction With Phosphodiesterase 5 Inhibitors Treatment In Patients With Cardiovascular Risk
NCT00874185
Last updated date
ABOUT THIS STUDY
Evaluate satisfaction in people treated with IPDE5 inhibitors over time
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Erectile Dysfunction
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- CV risk factors
- Male above 18
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- Non-informed consent
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Erectile DysfunctionEffect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males
NCT00313898
- Haifa,
Male
35 Years+
years
MULTIPLE SITES
Erectile DysfunctionA Relative Bioavailability Study Between Two Formulations Of Sildenafil Citrate
NCT00904748
- Braganca Paulista, SP
Male
18 Years+
years
MULTIPLE SITES
Erectile DysfunctionA Study to Compare the Blood Levels of Sildenafil Following Administration of an Experimental Tablet vs. the Conventional Oral Tablet in Healthy Subjects
NCT00866463
- New Haven, Connecticut
Male
18 Years+
years
MULTIPLE SITES
Erectile DysfunctionA Randomized, Open-Label, Crossover, Multicenter, Single Dose Comparator Study Evaluating Onset Of Penile Rigidity In Men With Erectile Dysfunction Who Are Treated With Sildenafil And Tadalafil
NCT00644956
- Oslo,
- Leeds,
Male
18 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title | Satisfaction With Phosphodiesterase 5 Inhibitors Treatment In Patients With Cardiovascular Risk | |||
| Official Title | Satisfaction With Treatment In Patients With Erectile Dysfunction And Cardiovascular Risk And/Or Previous Cardiovascular Event. | |||
| Brief Summary | Evaluate satisfaction in people treated with IPDE5 inhibitors over time | |||
| Detailed Description | 12 first patients that are eligible | |||
| Study Type | Observational | |||
| Study Design | Observational Model: Cohort Time Perspective: Prospective | |||
| Target Follow-Up Duration | Not Provided | |||
| Biospecimen | Not Provided | |||
| Sampling Method | Non-Probability Sample | |||
| Study Population | People with cv risk | |||
| Condition | Erectile Dysfunction | |||
| Intervention | Not Provided | |||
| Study Groups/Cohorts | Questionnaire
filling in questionnaires | |||
| Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status | Completed | |||
| Actual Enrollment | 720 | |||
| Original Actual Enrollment | 572 | |||
| Actual Study Completion Date | May 2008 | |||
| Actual Primary Completion Date | May 2008 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender |
| |||
| Ages | 18 Years and older (Adult, Older Adult) | |||
| Accepts Healthy Volunteers | No | |||
| Contacts | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries | Not Provided | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number | NCT00874185 | |||
| Other Study ID Numbers | A1481256 A1481256 | |||
| Has Data Monitoring Committee | No | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement | Not Provided | |||
| Responsible Party | Pfizer | |||
| Study Sponsor | Pfizer | |||
| Collaborators | Not Provided | |||
| Investigators |
| |||
| PRS Account | Pfizer | |||
| Verification Date | February 2013 | |||